Krystal Biotech (KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa

November 29, 2021 7:11 AM

Krystal Biotech (NASDAQ: KRYS) Surges ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found